Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: GLS001
MIFTS: 62

Gliosarcoma

Categories: Cancer diseases, Neuronal diseases, Rare diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Gliosarcoma

About this section

MalaCards integrated aliases for Gliosarcoma:

Name: Gliosarcoma 11 19 58 75 53 5 43 14 16 71
Glioblastoma with Sarcomatous Component 11
Sarcomatous Glioblastoma 19

Characteristics:


Prevelance:

<1/1000000 (Europe) 58

Age Of Onset:

Adult 58

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Neuronal diseases
See all MalaCards categories (disease lists)
ICD10: 32
Orphanet: 58  
Rare neurological diseases


External Ids:

Disease Ontology 11 DOID:3071
MeSH 43 D018316
NCIt 49 C3796
SNOMED-CT 68 35262004
ICD10 via Orphanet 32 C71.9
UMLS via Orphanet 72 C0206726
Orphanet 58 ORPHA251576
UMLS 71 C0206726
Sources

Summaries for Gliosarcoma

About this section

GARD: 19 A rare histological variant of glioblastoma (WHO grade IV) characterized by a biphasic tissue pattern with alternating areas displaying glial and mesenchymal differentiation (WHO).

MalaCards based summary: Gliosarcoma, also known as glioblastoma with sarcomatous component, is related to glioma susceptibility 1 and glioblastoma, and has symptoms including headache and seizures. An important gene associated with Gliosarcoma is MSH2 (MutS Homolog 2), and among its related pathways/superpathways are Apoptotic Pathways in Synovial Fibroblasts and ERK Signaling. The drugs Temozolomide and Sargramostim have been mentioned in the context of this disorder. Affiliated tissues include brain, eye and t cells, and related phenotypes are Decreased viability and Increased shRNA abundance (Z-score > 2)

Disease Ontology: 11 A gliomablastoma that is characterized by a biphasic tissue pattern with alternating areas displaying glial and mesenchymal differentiation.

Wikipedia: 75 Gliosarcoma is a rare type of glioma, a cancer of the brain that comes from glial, or supportive, brain... more...
Sources

Related Diseases for Gliosarcoma

About this section

Diseases related to Gliosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 453)
# Related Disease Score Top Affiliating Genes
1 glioma susceptibility 1 31.9 TP53 LZTR1 IDH1 H3-3A
2 glioblastoma 31.6 TP53 PTEN PIK3R1 PIK3CA MYCN MTOR
3 brain cancer 31.6 TP53 PTEN PIK3R1 PIK3CA MYCN MSH2
4 high grade glioma 31.5 TP53 PTEN PIK3CA MGMT EGFR ATM
5 central nervous system cancer 31.3 TP53 MGMT IDH1 EGFR
6 meningioma, familial 31.2 TP53 PTEN PIK3R1 PIK3CA MGMT LZTR1
7 glioma 31.1 TP53 PTEN PIK3CA MGMT IDH1 EGFR
8 sarcoma 31.1 TP53 PIK3CA MTOR HRAS FGFR1 BRAF
9 cellular ependymoma 31.1 MSH2 MGMT EGFR
10 oligodendroglioma 31.1 TP53 PTEN MSH2 MGMT IDH1 FGFR1
11 mixed cell type cancer 31.1 TP53 PTEN PIK3CA HRAS EGFR
12 diffuse astrocytoma 31.0 TP53 PTEN MGMT IDH1 H3-3A EGFR
13 anaplastic astrocytoma 31.0 TP53 PTEN MGMT IDH1 H3-3A EGFR
14 neurofibromatosis 30.8 TP53 PTEN MSH2 LZTR1 HRAS EGFR
15 neurofibroma 30.8 TP53 PTEN EGFR ATM
16 fibrillary astrocytoma 30.8 TP53 IDH1 H3-3A
17 malignant astrocytoma 30.8 TP53 PTEN MGMT IDH1 EGFR
18 low grade glioma 30.7 TP53 PTEN MTOR MGMT IDH1 H3-3A
19 neurofibromatosis, type i 30.7 TP53 PTEN MTOR MSH2 IDH1 HRAS
20 mixed glioma 30.7 TP53 PTEN MGMT IDH1 EGFR
21 chondroblastic osteosarcoma 30.7 TP53 IDH1 H3-3A
22 rhabdomyosarcoma 30.7 TP53 PTEN PIK3CA MYCN MTOR MSH2
23 pleomorphic xanthoastrocytoma 30.7 TP53 MGMT IDH1 H3-3A BRAF
24 medulloblastoma 30.7 TP53 PTEN PIK3CA MYCN MTOR MSH2
25 brain glioma 30.7 TP53 PTEN MGMT IDH1 H3-3A EGFR
26 liposarcoma 30.7 TP53 PTEN PIK3CA MSH2 FGFR1
27 ganglioglioma 30.7 TP53 MYCN H3-3A BRAF
28 anaplastic ependymoma 30.7 PTEN IDH1 H3-3A
29 hydrocephalus 30.6 TP53 PTEN MTOR FGFR3 FGFR1
30 adenoid cystic carcinoma 30.6 TP53 PTEN PIK3CA MYCN MGMT IDH1
31 giant cell glioblastoma 30.5 TP53 TACC3 TACC1 SEPTIN14 PTEN PIK3R1
32 brain glioblastoma multiforme 30.5 TP53 MGMT EGFR
33 lung benign neoplasm 30.5 TP53 MGMT HRAS EGFR
34 plexiform neurofibroma 30.5 TP53 LZTR1 HRAS EGFR
35 high-grade astrocytoma 30.5 TP53 PTEN
36 high grade ependymoma 30.5 MYCN MGMT IDH1 H3-3A
37 idh-wildtype glioblastoma 30.5 TP53 PTEN MGMT IDH1 H3-3A EGFR
38 carcinosarcoma 30.4 TP53 PTEN PIK3CA HRAS EGFR
39 inherited cancer-predisposing syndrome 30.4 TP53 PTEN MSH2 LZTR1 EGFR ATM
40 bap1 tumor predisposition syndrome 30.4 TP53 PTEN MSH2 LZTR1 EGFR ATM
41 lung cancer susceptibility 3 30.4 TP53 PIK3CA MGMT IDH1 HRAS FGFR3
42 exanthem 30.4 MTOR HRAS EGFR
43 peripheral nervous system disease 30.3 TP53 PTEN MYCN MTOR HRAS EGFR
44 pilocytic astrocytoma 30.3 TP53 TACC1 PTEN MGMT IDH1 HRAS
45 li-fraumeni syndrome 30.3 TP53 PTEN PIK3CA MYCN MSH2 IDH1
46 pancreatic cancer 30.2 TP53 PTEN PIK3R1 PIK3CA MTOR MSH2
47 adult brainstem gliosarcoma 11.2
48 gemistocytic astrocytoma 10.6 TP53 PTEN MGMT IDH1
49 mixed oligodendroglioma-astrocytoma 10.6 TP53 PTEN MGMT IDH1
50 spinal cord oligodendroglioma 10.6 TP53 MGMT IDH1 FGFR1 EGFR

Graphical network of the top 20 diseases related to Gliosarcoma:



Diseases related to Gliosarcoma
Sources

Symptoms & Phenotypes for Gliosarcoma

About this section

UMLS symptoms related to Gliosarcoma:


headache; seizures

GenomeRNAi Phenotypes related to Gliosarcoma according to GeneCards Suite gene sharing:

25 (show all 45)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.93 BRAF EGFR MTOR PIK3CA HRAS
2 Decreased viability GR00055-A-2 10.93 BRAF EGFR MTOR PIK3CA HRAS
3 Decreased viability GR00221-A-1 10.93 EGFR MTOR PIK3CA HRAS FGFR1 FGFR3
4 Decreased viability GR00221-A-2 10.93 PIK3CA HRAS FGFR1 FGFR3
5 Decreased viability GR00221-A-3 10.93 ATM HRAS FGFR3 PIK3R1
6 Decreased viability GR00221-A-4 10.93 ATM BRAF EGFR MTOR PIK3CA
7 Decreased viability GR00249-S 10.93 BRAF FGFR3
8 Decreased viability GR00301-A 10.93 BRAF
9 Decreased viability GR00342-S-1 10.93 MTOR
10 Decreased viability GR00342-S-2 10.93 MTOR
11 Decreased viability GR00381-A-1 10.93 BRAF
12 Decreased viability GR00386-A-1 10.93 FGFR1
13 Decreased viability GR00402-S-2 10.93 PIK3CA
14 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.35 FGFR1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-102 10.35 PIK3R1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-116 10.35 MSH2
17 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.35 EGFR
18 Increased shRNA abundance (Z-score > 2) GR00366-A-125 10.35 FGFR1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-14 10.35 MSH2
20 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.35 MSH2
21 Increased shRNA abundance (Z-score > 2) GR00366-A-169 10.35 FGFR1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-176 10.35 MSH2
23 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.35 PIK3R1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-183 10.35 FGFR1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-196 10.35 HRAS
26 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.35 PIK3R1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.35 EGFR
28 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.35 EGFR MSH2 PIK3R1
29 Increased shRNA abundance (Z-score > 2) GR00366-A-26 10.35 FGFR1
30 Increased shRNA abundance (Z-score > 2) GR00366-A-28 10.35 HRAS
31 Increased shRNA abundance (Z-score > 2) GR00366-A-34 10.35 PIK3R1
32 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.35 EGFR FGFR1 PIK3R1
33 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.35 FGFR1
34 Increased shRNA abundance (Z-score > 2) GR00366-A-50 10.35 FGFR1
35 Increased shRNA abundance (Z-score > 2) GR00366-A-53 10.35 MSH2
36 Increased shRNA abundance (Z-score > 2) GR00366-A-83 10.35 FGFR1 HRAS
37 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.35 EGFR
38 Increased shRNA abundance (Z-score > 2) GR00366-A-87 10.35 HRAS
39 Increased shRNA abundance (Z-score > 2) GR00366-A-91 10.35 EGFR
40 no effect GR00402-S-1 10.19 ATM BRAF EGFR FGFR1 FGFR3 H3-3A
41 no effect GR00402-S-2 10.19 ATM BRAF EGFR FGFR1 FGFR3 H3-3A
42 Decreased viability with paclitaxel GR00179-A-1 9.65 EGFR MTOR
43 Decreased viability with paclitaxel GR00179-A-2 9.65 MTOR
44 Decreased viability with paclitaxel GR00179-A-3 9.65 EGFR MTOR
45 Reduced mammosphere formation GR00396-S 9.5 ATM BRAF EGFR HRAS MTOR PIK3R1

MGI Mouse Phenotypes related to Gliosarcoma:

45 (show all 23)
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 10.47 ATM BRAF EGFR FGFR1 FGFR3 HRAS
2 homeostasis/metabolism MP:0005376 10.45 ATM BRAF EGFR FGFR1 FGFR3 H3-3A
3 growth/size/body region MP:0005378 10.44 ATM BRAF EGFR FGFR1 FGFR3 H3-3A
4 neoplasm MP:0002006 10.39 ATM BRAF EGFR FGFR3 HRAS MGMT
5 normal MP:0002873 10.38 BRAF EGFR FGFR1 FGFR3 H3-3A HRAS
6 cellular MP:0005384 10.33 ATM BRAF EGFR FGFR1 FGFR3 H3-3A
7 muscle MP:0005369 10.32 BRAF EGFR FGFR1 HRAS LZTR1 MTOR
8 endocrine/exocrine gland MP:0005379 10.3 ATM BRAF EGFR FGFR1 HRAS MGMT
9 renal/urinary system MP:0005367 10.28 BRAF EGFR FGFR1 FGFR3 H3-3A HRAS
10 no phenotypic analysis MP:0003012 10.25 EGFR FGFR1 FGFR3 HRAS MGMT MTOR
11 embryo MP:0005380 10.25 ATM BRAF EGFR FGFR1 H3-3A MTOR
12 limbs/digits/tail MP:0005371 10.22 BRAF EGFR FGFR1 FGFR3 MTOR MYCN
13 behavior/neurological MP:0005386 10.22 ATM BRAF FGFR1 FGFR3 H3-3A HRAS
14 cardiovascular system MP:0005385 10.21 ATM BRAF EGFR FGFR1 HRAS LZTR1
15 digestive/alimentary MP:0005381 10.19 BRAF EGFR FGFR1 FGFR3 HRAS MSH2
16 immune system MP:0005387 10.18 ATM BRAF EGFR FGFR1 FGFR3 IDH1
17 adipose tissue MP:0005375 10.16 ATM BRAF EGFR MTOR PIK3CA PIK3R1
18 craniofacial MP:0005382 10.13 BRAF EGFR FGFR1 FGFR3 HRAS LZTR1
19 skeleton MP:0005390 10.07 BRAF EGFR FGFR1 FGFR3 HRAS IDH1
20 respiratory system MP:0005388 10.02 BRAF EGFR FGFR3 HRAS IDH1 MGMT
21 hematopoietic system MP:0005397 10 ATM BRAF EGFR FGFR1 FGFR3 IDH1
22 mortality/aging MP:0010768 9.91 ATM BRAF EGFR FGFR1 FGFR3 H3-3A
23 integument MP:0010771 9.36 ATM BRAF EGFR FGFR1 FGFR3 HRAS
Sources

Drugs & Therapeutics for Gliosarcoma

About this section

Drugs for Gliosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 223)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Temozolomide Approved, Investigational Phase 3 85622-93-1 5394
2
Sargramostim Approved, Investigational Phase 3 123774-72-1
3
Nivolumab Approved Phase 2, Phase 3 946414-94-4
4
Ipilimumab Approved Phase 2, Phase 3 477202-00-9
5
Molgramostim Investigational Phase 3 99283-10-0
6
Rindopepimut Investigational Phase 3 1108208-65-6
7
Veliparib Investigational Phase 2, Phase 3 912444-00-9 11960529
8 Alkylating Agents Phase 3
9 Antineoplastic Agents, Alkylating Phase 3
10 Immunoglobulin G Phase 3
11 Immunologic Factors Phase 3
12 Endothelial Growth Factors Phase 3
13 Mitogens Phase 2, Phase 3
14 Immunoconjugates Phase 2, Phase 3
15 Poly(ADP-ribose) Polymerase Inhibitors Phase 2, Phase 3
16 Immune Checkpoint Inhibitors Phase 2, Phase 3
17
Iodine Approved, Investigational Phase 2 7553-56-2 807
18
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 5284616 6436030
19
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
20
Clotrimazole Approved, Vet_approved Phase 1, Phase 2 23593-75-1 2812
21
Aflibercept Approved Phase 2 862111-32-8 124490314
22
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
23
Lapatinib Approved, Investigational Phase 2 231277-92-2, 388082-78-8 208908
24
Acetic acid Approved Phase 2 64-19-7 176
25
Topotecan Approved, Investigational Phase 2 123948-87-8, 119413-54-6 60699 60700
26
Romidepsin Approved, Investigational Phase 1, Phase 2 128517-07-7 5352062
27
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
28
Valproic acid Approved, Investigational Phase 2 99-66-1 3121
29
Benzocaine Approved, Investigational Phase 2 1994-09-7, 94-09-7 2337
30
Tannic acid Approved Phase 2 1401-55-4 16129878 16129778
31
Etoposide Approved Phase 2 33419-42-0 36462
32
Hydroxyurea Approved Phase 2 127-07-1 3657
33
Lenalidomide Approved Phase 2 191732-72-6 216326
34
Aldesleukin Approved Phase 1, Phase 2 110942-02-4
35
Fludarabine Approved Phase 1, Phase 2 75607-67-9, 21679-14-1 30751 657237
36
Coenzyme M Approved, Investigational Phase 1, Phase 2 3375-50-6 598 23662354
37
Nintedanib Approved Phase 2 656247-17-5 135423438 9809715
38
Mebendazole Approved, Vet_approved Phase 1, Phase 2 31431-39-7 4030
39
Piperazine Approved, Vet_approved Phase 1, Phase 2 110-85-0 4837
40
Carboplatin Approved Phase 1, Phase 2 41575-94-4 10339178 38904
41
Vincristine Approved, Investigational Phase 1, Phase 2 2068-78-2, 57-22-7 5978
42
Sodium citrate Approved, Investigational Phase 1, Phase 2 68-04-2 23431961
43
Paclitaxel Approved, Vet_approved Phase 1, Phase 2 33069-62-4 36314
44
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
45
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
46
Atezolizumab Approved, Investigational Phase 1, Phase 2 1380723-44-3
47
Flucytosine Approved, Investigational Phase 1, Phase 2 2022-85-7 3366
48
Pembrolizumab Approved Phase 2 1374853-91-4 254741536
49
Sunitinib Approved, Investigational Phase 2 557795-19-4 5329102
50
Loperamide Approved Phase 2 53179-11-6 3955

Interventional clinical trials:

(show top 50) (show all 231)
# Name Status NCT ID Phase Drugs
1 A Phase III Study of Radiation Therapy (RT) and O6-Benzylguanine (O6-BG) Plus BCNU Versus RT and BCNU Alone for Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma Completed NCT00017147 Phase 3 carmustine;O6-Benzylguanine
2 A Randomized, Placebo Controlled Phase 3 Study of ABT-414 With Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1) Completed NCT02573324 Phase 2, Phase 3 Temozolomide;ABT-414;Placebo for ABT-414
3 Phase III Double-blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed NCT00884741 Phase 3 Temozolomide
4 An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF With Adjuvant Temozolomide in Patients With Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma Completed NCT01480479 Phase 3 Rindopepimut (CDX-110) with GM-CSF;Temozolomide;KLH
5 Phase III Trial Comparing Conventional Adjuvant Temozolomide With Dose-Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed NCT00304031 Phase 3 Concurrent temozolomide;100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle;75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle
6 A Phase III Trial of Gleostine® (Lomustine)-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients With Methylated MGMT Promoter Glioblastoma Recruiting NCT05095376 Phase 3 Lomustine;Temozolomide
7 A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation Active, not recruiting NCT02152982 Phase 2, Phase 3 Temozolomide;Veliparib
8 A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma Suspended NCT04396860 Phase 2, Phase 3 Temozolomide
9 A Phase 2 Study of AR-67 (7-t-butyldimethylsiltyl-10-hydroxy-camptothecin) in Adult Patients With Recurrence of Glioblastoma Multiforme (GBM) or Gliosarcoma Unknown status NCT01124539 Phase 2 AR-67 (7-t-butyldimethylsiltyl-10-hydroxy-camptothecin)
10 Phase IIb Trial Evaluations Of The Effectiveness Of Treatment Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475 (Pembrolizumab) Unknown status NCT02430363 Phase 1, Phase 2 MK - 3475
11 A Phase II Open-Label, Multiple-Dose Study of Intracavitary Administered 131-I-TM-601 in Adult Patients With Recurrent High-Grade Glioma Unknown status NCT00114309 Phase 2 131-I-TM-601;131I-TM601
12 Phase II Pilot Trial of Hyperbaric Hyperoxygenation in Conjunction With Radiotherapy and Temozolomide In Adults With Newly Diagnosed Glioblastomas Unknown status NCT00936052 Phase 2
13 Phase I/II Clinical Trial of the Safety, Tolerability, and Anti-tumor Efficacy of the IGF-1R Inhibitor, AXL1717 (Picropodophyllin), in the Treatment of Recurrent Malignant Astrocytomas Unknown status NCT01721577 Phase 1, Phase 2 AXL1717
14 Randomized Phase II Trial of Concurrent Bevacizumab and Re-Irradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma Unknown status NCT01730950 Phase 2
15 A Phase I/II Study of ABT-888, An Oral Poly(ADP-ribose) Polymerase Inhibitor, and Concurrent Radiation Therapy, Followed by ABT-888 and Temozolomide, in Children With Newly Diagnosed Diffuse Pontine Gliomas (DIPG) Completed NCT01514201 Phase 1, Phase 2 Temozolomide;Veliparib
16 Phase 1/2 Study of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma Completed NCT00402116 Phase 1, Phase 2 enzastaurin;temozolomide
17 A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192) Completed NCT02798406 Phase 2
18 A Phase II Study of Bevacizumab Plus Temodar and Tarceva After Radiation Therapy and Temodar in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma Who Are Stable Following Radiation Completed NCT00525525 Phase 2 Bevacizumab;Tarceva;Temozolomide
19 Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma Completed NCT01609790 Phase 2
20 Phase II Study of Tarceva Plus Temodar During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme and Gliosarcoma Completed NCT00187486 Phase 2 Tarceva;Temodar
21 Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma Completed NCT00335764 Phase 1, Phase 2 sorafenib tosylate;erlotinib hydrochloride;tipifarnib;temsirolimus
22 Phase II Trial of Erlotinib Plus Sirolimus for Patients With Recurrent Malignant Glioma Multiforme Completed NCT00672243 Phase 2 Erlotinib + sirolimus
23 Phase II Trial of Bevacizumab Plus Erlotinib for Patients With Recurrent Malignant Glioma Completed NCT00671970 Phase 2 Bevacizumab and Erlotinib
24 A Phase Ib/II Study of AZD2171 in Combination With Daily Temozolomide and Radiation in Patients With Newly Diagnosed Glioblastoma Not Taking Enzyme-Inducing Anti-epileptic Drugs Completed NCT00662506 Phase 1, Phase 2 Cediranib Maleate;Temozolomide
25 A Phase I/II Study of the Combination of Indoximod and Temozolomide for Adult Patients With Temozolomide-Refractory Primary Malignant Brain Tumors Completed NCT02052648 Phase 1, Phase 2 Indoximod;Temozolomide;Bevacizumab
26 A Phase II Trial of Erlotinib (OSI-774) and Sorafenib (BAY 43-9006) for Patients With Progression or Recurrent Glioblastoma Multiforme Completed NCT00445588 Phase 2 erlotinib hydrochloride;sorafenib tosylate
27 Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme Completed NCT00423735 Phase 2 Dasatinib
28 A Feasibility Assessment and a Phase I/II Trial of MLN518 for Treatment of Patients With Recurrent Glioblastoma Completed NCT00379080 Phase 1, Phase 2 tandutinib
29 BrUOG 263: PSMA ADC for Recurrent Glioblastoma Multiforme (GBM): A Phase II Brown University Oncology Research Group Study Completed NCT01856933 Phase 2 PSMA ADC
30 Phase II Study of Vorinostat (SAHA) in Combination With Bortezomib (PS-341) in Patients With Recurrent Glioblastoma Multiforme Completed NCT00641706 Phase 2 vorinostat;bortezomib
31 A Phase II Study of Bendamustine in the Treatment of Recurrent High-Grade Gliomas (Anaplastic Gliomas and Glioblastoma) Completed NCT00823797 Phase 2 Bendamustine Hydrochloride
32 Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Completed NCT00731731 Phase 1, Phase 2 Temozolomide;Vorinostat
33 A Phase 2 Study of R-(-)-Gossypol (Ascenta's AT-101) in Recurrent Glioblastoma Multiforme Completed NCT00540722 Phase 2 R-(-)-gossypol acetic acid
34 Phase I/II Study of ZD6474 (Vandetanib) With Radiation Therapy and Concomitant and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma Completed NCT00441142 Phase 1, Phase 2 ZD6474;temozolomide
35 A Phase I/II Study of Local Field Irradiation and Temozolomide Followed by Continuous Infusion Plerixafor as an Upfront Therapy for Newly Diagnosed Glioblastoma GBM Completed NCT01977677 Phase 1, Phase 2 temozolomide;plerixafor
36 A Phase 2 Trial of Tandutinib in Combination With Bevacizumab for Patients With Recurrent High-Grade Gliomas Completed NCT00667394 Phase 2 MLN-518 (Tandutinib)
37 Phase 2 Study of Dose-Intense Temozolomide in Recurrent Glioblastoma Completed NCT00657267 Phase 2 Temozolomide
38 A Phase I/II Clinical Trial of Autologous CMV-Specific Cytotoxic T Cells for GBM Patients Completed NCT02661282 Phase 1, Phase 2 Temozolomide
39 A Pharmacokinetic and Phase 2 Study of Sunitinib Malate in Recurrent Malignant Gliomas Completed NCT00499473 Phase 2 sunitinib malate
40 A Phase II Trial of GW786034 (Pazopanib) in Patients With Recurrent Glioblastoma Completed NCT00459381 Phase 2 pazopanib hydrochloride
41 A Prospective Phase II Trial of NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma Completed NCT01894061 Phase 2
42 A Phase II Trial of Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A)Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab Completed NCT01931098 Phase 2 topotecan;pazopanib
43 A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma Completed NCT00433381 Phase 2 Irinotecan Hydrochloride;Temozolomide
44 Phase II Single Arm Trial of VEGF Trap in Patients With Recurrent Temozolomide-Resistant Malignant Gliomas Completed NCT00369590 Phase 2
45 A Biomarker and Phase II Study of GW572016 in Recurrent Malignant Glioma Completed NCT00107003 Phase 2 lapatinib ditosylate
46 A Phase I-II Trial of Depsipeptide in Patients With Recurrent High-Grade Gliomas Completed NCT00085540 Phase 1, Phase 2 depsipeptide
47 Phase II Study Of ZD1839 (NSC 715055) In Newly Diagnosed Patients With Glioblastoma (Grade 4 Astrocytoma) Completed NCT00014170 Phase 2 gefitinib
48 A Phase II Study of CCI-779 in Patients With Recurrent Glioblastoma Multiforme Completed NCT00016328 Phase 2 temsirolimus
49 Avastin in Combination With Radiation and Temozolomide Followed by Avastin, Temozolomide, and Topotecan for Glioblastoma Multiformes and Gliosarcomas Completed NCT01004874 Phase 2 Bevacizumab;Temozolomide;Topotecan
50 A Phase 2 Study of Valproic Acid and Radiation, Followed by Maintenance Valproic Acid and Bevacizumab in Children With Newly Diagnosed High-grade Gliomas or Brainstem Gliomas Completed NCT00879437 Phase 2 Valproic acid;Bevacizumab

Search NIH Clinical Center for Gliosarcoma

Cochrane evidence based reviews: gliosarcoma

Sources

Genetic Tests for Gliosarcoma

About this section
Sources

Anatomical Context for Gliosarcoma

About this section

Organs/tissues related to Gliosarcoma:

MalaCards : Brain, Eye, T Cells, Bone Marrow, Nk Cells, Endothelial, Spinal Cord
Sources

Publications for Gliosarcoma

About this section

Articles related to Gliosarcoma:

(show top 50) (show all 1093)
# Title Authors PMID Year
1
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 5
26619011 2016
2
Treatment of rat gliosarcoma brain tumors by HSV-based multigene therapy combined with radiosurgery. 53 62
14529825 2003
3
Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo. 53 62
11306477 2001
4
Characterisation of molecular alterations in microdissected archival gliomas. 53 62
11355303 2001
5
Genetic profile of gliosarcomas. 53 62
10666371 2000
6
Amplification and expression of cyclin D genes (CCND1, CCND2 and CCND3) in human malignant gliomas. 53 62
10416984 1999
7
Connexins are expressed in primary brain tumors and enhance the bystander effect in gene therapy. 53 62
9932890 1999
8
The effect of ganciclovir on herpes simplex virus-mediated oncolysis. 53 62
9224416 1997
9
Rapid detection of transferrin receptor expression on glioma cell lines by using magnetic microspheres. 53 62
8264887 1993
10
Gliosarcoma of the posterior fossa with features of a malignant fibrous histiocytoma. 53 62
2154322 1990
11
Relationship between RANO-PRO Working Group standardised priority constructs and disease progression among malignant glioma patients: A retrospective cohort study. 62
36386035 2023
12
A rare, giant, lateral intraventricular gliosarcoma. 62
36425394 2023
13
Towards differentiation of brain tumor from radiation necrosis using multi-parametric MRI: Preliminary results at 4.7 T using rodent models. 62
36209946 2022
14
Usefulness of circulating tumor DNA from cerebrospinal fluid in recurrent high-grade glioma. 62
35871016 2022
15
Distinct metabolic hallmarks of WHO classified adult glioma subtypes. 62
35157758 2022
16
Rodent Brain Tumor Models for Studies Focusing on Boron Neutron Capture Therapy. 62
36125407 2022
17
Multidisciplinary approaches to gliosarcoma: A case report and review of the literature. 62
36017117 2022
18
Gliosarcoma with unusual glial components: Two case reports. 62
35644835 2022
19
Primary gliosarcoma with widespread extracranial metastases-spatiotemporal morphological variation. 62
35932030 2022
20
Primary versus secondary gliosarcoma: a systematic review and meta-analysis. 62
35768633 2022
21
Gliosarcoma With Glioneuronal and Rhabdomyosarcoma Components. 62
35959193 2022
22
Ketogenic Metabolic Therapy for Glioma. 62
35923675 2022
23
Meloxicam can Potentiate the Therapeutic Effects of Synchrotron Microbeam Radiation Therapy on High-Grade Glioma Bearing Rats. 62
35245385 2022
24
Chasing a rarity: a retrospective single-center evaluation of prognostic factors in primary gliosarcoma. 62
34939129 2022
25
Survival outcomes associated with MGMT promoter methylation and temozolomide in gliosarcoma patients. 62
35474499 2022
26
Glioblastoma: Changing concepts in the WHO CNS5 classification. 62
35562131 2022
27
Optimization of a flexible fiber-optic probe for epi-mode quantitative phase imaging. 62
36221587 2022
28
Rat and Mouse Brain Tumor Models for Experimental Neuro-Oncology Research. 62
35446393 2022
29
Gliosarcoma with direct involvement of the oculomotor nerve: Case report and literature review. 62
35169418 2022
30
Gliosarcoma with osteosarcomatous component: A case report and short review illustration. 62
35278815 2022
31
Clinical and survival characteristics of primary and secondary gliosarcoma patients. 62
35101778 2022
32
Primary intraventricular gliosarcoma on MRI: A challenging diagnosis. 62
35003460 2022
33
Photodynamic effect of protoporphyrin IX in gliosarcoma 9l/lacZ cell line. 62
34863947 2022
34
Sporadic and Lynch syndrome-associated mismatch repair-deficient brain tumors. 62
34848827 2022
35
Combined intracranial Acriflavine, temozolomide and radiation extends survival in a rat glioma model. 62
34968646 2022
36
A Unique Case Report of Infant-Type Hemispheric Glioma (Gliosarcoma Subtype) with TPR-NTRK1 Fusion Treated with Larotrectinib. 62
35034013 2022
37
CNS Histoplasmosis as a Gliosarcoma mimicker: The diagnostic dilemma of solitary brain lesions. 62
35024338 2022
38
Can a signature molecular-profile define disparate survival in BRAF-positive Gliosarcoma and identify novel targets for therapeutic intervention? 62
35381788 2022
39
Primary intramedullary spinal gliosarcoma: An unusual presentation. 62
35381798 2022
40
Computed Tomography, Magnetic Resonance Imaging, and Pathological Features of Gliosarcoma. 62
36387942 2022
41
Gliosarcoma with Systemic Metastasis Showing Favorable Response to Ifosfamide, Carboplatin, and Etoposide Chemotherapy: An Autopsy Case Report. 62
36186622 2022
42
Zinc pthalocyanine loaded poly (lactic acid) nanoparticles by double emulsion methodology for photodynamic therapy against 9 L/LacZ gliosarcoma cells. 62
34517784 2022
43
Gliosarcoma: The Distinct Genomic Alterations Identified by Comprehensive Analysis of Copy Number Variations. 62
35757013 2022
44
Efficacy and safety of nivolumab in Japanese patients with first recurrence of glioblastoma: an open-label, non-comparative study. 62
34586548 2021
45
Treatments of gliosarcoma of the brain: a systematic review and meta-analysis. 62
33156945 2021
46
Raman imaging and statistical methods for analysis various type of human brain tumors and breast cancers. 62
34175760 2021
47
Genetic alteration and clonal evolution of primary glioblastoma into secondary gliosarcoma. 62
34605602 2021
48
GammaTile for Gliomas: A Single-Center Case Series. 62
34925992 2021
49
Pediatric Gliosarcoma With and Without Neurofibromatosis Type 1: A Whole-exome Comparison of 2 Patients. 62
33235140 2021
50
Do gliosarcomas have distinct imaging features on routine MRI? 62
33928823 2021
Sources

Variations for Gliosarcoma

About this section

ClinVar genetic disease variations for Gliosarcoma:

5 (show top 50) (show all 233)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 H3-3A NM_002107.7(H3-3A):c.103G>A (p.Gly35Arg) SNV Other
 438766 rs1553260624 GRCh37: 1:226252155-226252155
GRCh38: 1:226064454-226064454
2 MED12 NM_005120.3(MED12):c.5980C>T (p.Arg1994Trp) SNV Other
 438772 rs1556339256 GRCh37: X:70357729-70357729
GRCh38: X:71137879-71137879
3 BCOR NM_001123385.2(BCOR):c.3883_3884del (p.Leu1296fs) MICROSAT Other
 284290 rs886042842 GRCh37: X:39922288-39922289
GRCh38: X:40063035-40063036
4 MSH2 NM_000251.3(MSH2):c.1958_1965del (p.Asn653fs) DEL Pathogenic
 590849 rs1558518449 GRCh37: 2:47702360-47702367
GRCh38: 2:47475221-47475228
5 NRAS NM_002524.5(NRAS):c.181C>A (p.Gln61Lys) SNV Likely Pathogenic
 73058 rs121913254 GRCh37: 1:115256530-115256530
GRCh38: 1:114713909-114713909
6 TP53 NM_000546.6(TP53):c.641A>T (p.His214Leu) SNV Likely Pathogenic
 376616 rs1057519992 GRCh37: 17:7578208-7578208
GRCh38: 17:7674890-7674890
7 PIK3CA NM_006218.4(PIK3CA):c.241G>A (p.Glu81Lys) SNV Likely Pathogenic
 376478 rs1057519929 GRCh37: 3:178916854-178916854
GRCh38: 3:179199066-179199066
8 HRAS, LRRC56 NM_005343.4(HRAS):c.34G>T (p.Gly12Cys) SNV Likely Pathogenic
 12613 rs104894229 GRCh37: 11:534289-534289
GRCh38: 11:534289-534289
9 NRAS NM_002524.5(NRAS):c.182A>G (p.Gln61Arg) SNV Likely Pathogenic
 13900 rs11554290 GRCh37: 1:115256529-115256529
GRCh38: 1:114713908-114713908
10 HRAS, LRRC56 NM_005343.4(HRAS):c.35G>C (p.Gly12Ala) SNV Likely Pathogenic
 12603 rs104894230 GRCh37: 11:534288-534288
GRCh38: 11:534288-534288
11 IDH1 NM_005896.4(IDH1):c.395G>A (p.Arg132His) SNV Likely Pathogenic
 156444 rs121913500 GRCh37: 2:209113112-209113112
GRCh38: 2:208248388-208248388
12 TP53 NM_000546.6(TP53):c.659A>G (p.Tyr220Cys) SNV Likely Pathogenic
 127819 rs121912666 GRCh37: 17:7578190-7578190
GRCh38: 17:7674872-7674872
13 TP53 NM_000546.6(TP53):c.584T>A (p.Ile195Asn) SNV Likely Pathogenic
 376618 rs760043106 GRCh37: 17:7578265-7578265
GRCh38: 17:7674947-7674947
14 TP53 NM_000546.6(TP53):c.374C>T (p.Thr125Met) SNV Likely Pathogenic
 183748 rs786201057 GRCh37: 17:7579313-7579313
GRCh38: 17:7675995-7675995
15 TP53 NM_000546.6(TP53):c.722C>G (p.Ser241Cys) SNV Likely Pathogenic
 177791 rs28934573 GRCh37: 17:7577559-7577559
GRCh38: 17:7674241-7674241
16 TP53 NM_000546.6(TP53):c.730G>T (p.Gly244Cys) SNV Likely Pathogenic
 376599 rs1057519989 GRCh37: 17:7577551-7577551
GRCh38: 17:7674233-7674233
17 TP53 NM_000546.6(TP53):c.742C>T (p.Arg248Trp) SNV Likely Pathogenic
 12347 rs121912651 GRCh37: 17:7577539-7577539
GRCh38: 17:7674221-7674221
18 TP53 NM_000546.6(TP53):c.796G>C (p.Gly266Arg) SNV Likely Pathogenic
 376605 rs1057519990 GRCh37: 17:7577142-7577142
GRCh38: 17:7673824-7673824
19 TP53 NM_000546.6(TP53):c.712T>C (p.Cys238Arg) SNV Likely Pathogenic
 376576 rs1057519981 GRCh37: 17:7577569-7577569
GRCh38: 17:7674251-7674251
20 TP53 NM_000546.6(TP53):c.374C>G (p.Thr125Arg) SNV Likely Pathogenic
 376667 rs786201057 GRCh37: 17:7579313-7579313
GRCh38: 17:7675995-7675995
21 TP53 NM_000546.6(TP53):c.535C>T (p.His179Tyr) SNV Likely Pathogenic
 127815 rs587780070 GRCh37: 17:7578395-7578395
GRCh38: 17:7675077-7675077
22 TP53 NM_000546.6(TP53):c.580C>T (p.Leu194Phe) SNV Likely Pathogenic
 127817 rs587780071 GRCh37: 17:7578269-7578269
GRCh38: 17:7674951-7674951
23 TP53 NM_000546.6(TP53):c.658T>C (p.Tyr220His) SNV Likely Pathogenic
 376687 rs530941076 GRCh37: 17:7578191-7578191
GRCh38: 17:7674873-7674873
24 TP53 NM_000546.6(TP53):c.637C>G (p.Arg213Gly) SNV Likely Pathogenic
 376651 rs397516436 GRCh37: 17:7578212-7578212
GRCh38: 17:7674894-7674894
25 TP53 NM_000546.6(TP53):c.817C>A (p.Arg273Ser) SNV Likely Pathogenic
 376656 rs121913343 GRCh37: 17:7577121-7577121
GRCh38: 17:7673803-7673803
26 TP53 NM_000546.6(TP53):c.733G>A (p.Gly245Ser) SNV Likely Pathogenic
 12365 rs28934575 GRCh37: 17:7577548-7577548
GRCh38: 17:7674230-7674230
27 TP53 NM_000546.6(TP53):c.701A>G (p.Tyr234Cys) SNV Likely Pathogenic
 127820 rs587780073 GRCh37: 17:7577580-7577580
GRCh38: 17:7674262-7674262
28 TP53 NM_000546.6(TP53):c.638G>A (p.Arg213Gln) SNV Likely Pathogenic
 135359 rs587778720 GRCh37: 17:7578211-7578211
GRCh38: 17:7674893-7674893
29 TP53 NM_000546.6(TP53):c.824G>C (p.Cys275Ser) SNV Likely Pathogenic
 376583 rs863224451 GRCh37: 17:7577114-7577114
GRCh38: 17:7673796-7673796
30 TP53 NM_000546.6(TP53):c.536A>G (p.His179Arg) SNV Likely Pathogenic
 376606 rs1057519991 GRCh37: 17:7578394-7578394
GRCh38: 17:7675076-7675076
31 TP53 NM_000546.6(TP53):c.731G>A (p.Gly244Asp) SNV Likely Pathogenic
 372785 rs985033810 GRCh37: 17:7577550-7577550
GRCh38: 17:7674232-7674232
32 TP53 NM_000546.6(TP53):c.845G>A (p.Arg282Gln) SNV Likely Pathogenic
 237956 rs730882008 GRCh37: 17:7577093-7577093
GRCh38: 17:7673775-7673775
33 TP53 NM_000546.6(TP53):c.536A>T (p.His179Leu) SNV Likely Pathogenic
 376608 rs1057519991 GRCh37: 17:7578394-7578394
GRCh38: 17:7675076-7675076
34 TP53 NM_000546.6(TP53):c.746G>C (p.Arg249Thr) SNV Likely Pathogenic
 376015 rs587782329 GRCh37: 17:7577535-7577535
GRCh38: 17:7674217-7674217
35 TP53 NM_000546.6(TP53):c.797G>T (p.Gly266Val) SNV Likely Pathogenic
 233303 rs193920774 GRCh37: 17:7577141-7577141
GRCh38: 17:7673823-7673823
36 TP53 NM_000546.6(TP53):c.844C>T (p.Arg282Trp) SNV Likely Pathogenic
 12364 rs28934574 GRCh37: 17:7577094-7577094
GRCh38: 17:7673776-7673776
37 TP53 NM_000546.6(TP53):c.842A>T (p.Asp281Val) SNV Likely Pathogenic
 182968 rs587781525 GRCh37: 17:7577096-7577096
GRCh38: 17:7673778-7673778
38 TP53 NM_000546.6(TP53):c.713G>C (p.Cys238Ser) SNV Likely Pathogenic
 376575 rs730882005 GRCh37: 17:7577568-7577568
GRCh38: 17:7674250-7674250
39 TP53 NM_000546.6(TP53):c.613T>C (p.Tyr205His) SNV Likely Pathogenic
 376685 rs1057520008 GRCh37: 17:7578236-7578236
GRCh38: 17:7674918-7674918
40 TP53 NM_000546.6(TP53):c.658T>A (p.Tyr220Asn) SNV Likely Pathogenic
 376688 rs530941076 GRCh37: 17:7578191-7578191
GRCh38: 17:7674873-7674873
41 TP53 NM_000546.6(TP53):c.725G>T (p.Cys242Phe) SNV Likely Pathogenic
 376578 rs121912655 GRCh37: 17:7577556-7577556
GRCh38: 17:7674238-7674238
42 TP53 NM_000546.6(TP53):c.844C>G (p.Arg282Gly) SNV Likely Pathogenic
 140821 rs28934574 GRCh37: 17:7577094-7577094
GRCh38: 17:7673776-7673776
43 TP53 NM_000546.6(TP53):c.583A>T (p.Ile195Phe) SNV Likely Pathogenic
 376617 rs942158624 GRCh37: 17:7578266-7578266
GRCh38: 17:7674948-7674948
44 TP53 NM_000546.6(TP53):c.764T>A (p.Ile255Asn) SNV Likely Pathogenic
 232289 rs876659675 GRCh37: 17:7577517-7577517
GRCh38: 17:7674199-7674199
45 TP53 NM_000546.6(TP53):c.733G>T (p.Gly245Cys) SNV Likely Pathogenic
 12349 rs28934575 GRCh37: 17:7577548-7577548
GRCh38: 17:7674230-7674230
46 BRAF NM_004333.6(BRAF):c.1799T>A (p.Val600Glu) SNV Likely Pathogenic
 13961 rs113488022 GRCh37: 7:140453136-140453136
GRCh38: 7:140753336-140753336
47 PTEN NM_000314.8(PTEN):c.698G>A (p.Arg233Gln) SNV Likely Pathogenic
 376510 rs770025422 GRCh37: 10:89717673-89717673
GRCh38: 10:87957916-87957916
48 TP53 NM_000546.6(TP53):c.734G>C (p.Gly245Ala) SNV Likely Pathogenic
 265357 rs121912656 GRCh37: 17:7577547-7577547
GRCh38: 17:7674229-7674229
49 TP53 NM_000546.6(TP53):c.734G>T (p.Gly245Val) SNV Likely Pathogenic
 376603 rs121912656 GRCh37: 17:7577547-7577547
GRCh38: 17:7674229-7674229
50 TP53 NM_000546.6(TP53):c.646G>T (p.Val216Leu) SNV Likely Pathogenic
 376670 rs730882025 GRCh37: 17:7578203-7578203
GRCh38: 17:7674885-7674885
Sources

Expression for Gliosarcoma

About this section
Search GEO for disease gene expression data for Gliosarcoma.
Sources

Pathways for Gliosarcoma

About this section

Pathways related to Gliosarcoma according to GeneCards Suite gene sharing:

(show top 50) (show all 158)
# Super pathways Score Top Affiliating Genes
1
Apoptotic Pathways in Synovial Fibroblasts 64
Show member pathways
 13.95 TP53 PTEN PIK3R1 HRAS H3-3A FGFR3
2
ERK Signaling 64
Show member pathways
 13.94 TP53 PTEN PIK3R1 MTOR HRAS H3-3A
3
Signal Transduction 66
13.86 TP53 TACC3 PTEN PIK3R1 PIK3CA MYCN
4
Disease 66
Show member pathways
 13.85 ATM BRAF EGFR FGFR1 FGFR3 H3-3A
5
MIF Mediated Glucocorticoid Regulation 64
Show member pathways
 13.73 TP53 PIK3R1 MTOR HRAS FGFR3 FGFR1
6
Activation of cAMP-Dependent PKA 64
Show member pathways
 13.66 PIK3R1 MTOR HRAS H3-3A FGFR3 FGFR1
7
TGF-Beta Pathway 64
Show member pathways
 13.65 BRAF EGFR FGFR1 FGFR3 H3-3A HRAS
8
Akt Signaling 64
Show member pathways
 13.53 TP53 PTEN PIK3R1 MTOR HRAS FGFR3
9
RAF/MAP kinase cascade 66
Show member pathways
 13.5 BRAF EGFR FGFR1 FGFR3 HRAS MTOR
10
Prolactin Signaling 64
Show member pathways
 13.44 TP53 PTEN PIK3R1 PIK3CA MTOR MGMT
11
PIP3 activates AKT signaling 66
Show member pathways
 13.2 TP53 PTEN PIK3R1 PIK3CA MTOR FGFR3
12
Phospholipase-C Pathway 64
Show member pathways
 13.19 TP53 PTEN PIK3R1 MTOR HRAS FGFR3
13
p70S6K Signaling 64
Show member pathways
 13.16 EGFR FGFR1 FGFR3 HRAS MTOR PIK3R1
14
PI3K-Akt signaling pathway 74
Show member pathways
 13.06 EGFR FGFR1 FGFR3 HRAS MTOR PIK3CA
15
TNFR1 Pathway 64
Show member pathways
 13.04 TP53 PTEN PIK3R1 PIK3CA MTOR HRAS
16
Beta-Adrenergic Signaling 64
Show member pathways
 12.98 PIK3R1 PIK3CA MTOR HRAS BRAF
17
IL-9 Signaling Pathways 65
Show member pathways
 12.98 BRAF HRAS MTOR PIK3CA PIK3R1 PTEN
18
Development Angiotensin activation of ERK 22
Show member pathways
 12.95 PIK3R1 PIK3CA HRAS EGFR BRAF
19
Toll-like receptor signaling pathway 74
Show member pathways
 12.94 TP53 PIK3R1 PIK3CA HRAS BRAF
20
Alzheimer's disease and miRNA effects 74
Show member pathways
 12.93 BRAF HRAS MTOR PIK3CA PIK3R1
21
NFAT and Cardiac Hypertrophy 64
Show member pathways
 12.93 PTEN PIK3R1 PIK3CA MTOR HRAS FGFR3
22
Signaling by Receptor Tyrosine Kinases 66
12.9 PIK3R1 PIK3CA MYCN MTOR HRAS FGFR3
23
Translation Insulin regulation of translation 22
Show member pathways
 12.87 EGFR HRAS MTOR PIK3CA PIK3R1 PTEN
24
Insulin receptor signalling cascade 66
Show member pathways
 12.82 PIK3R1 PIK3CA HRAS FGFR3 FGFR1
25
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling 66
Show member pathways
 12.82 PTEN PIK3R1 PIK3CA MTOR FGFR3 FGFR1
26
4-1BB Pathway 64
Show member pathways
 12.78 TP53 PIK3R1 HRAS EGFR BRAF
27
Immune response IL-23 signaling pathway 22
Show member pathways
 12.73 TP53 PIK3R1 PIK3CA MSH2 HRAS EGFR
28
Overview of interferons-mediated signaling pathway 74
Show member pathways
 12.73 TP53 PIK3R1 PIK3CA MTOR HRAS FGFR3
29
Negative regulation of FGFR1 signaling 66
Show member pathways
 12.72 PIK3R1 PIK3CA HRAS FGFR3 FGFR1 BRAF
30
Malignant pleural mesothelioma 74
12.72 ATM EGFR FGFR1 FGFR3 HRAS MTOR
31
Angiopoietin-like protein 8 regulatory pathway 74
Show member pathways
 12.65 HRAS MTOR PIK3CA PIK3R1 PTEN
32
DNA Damage 3
12.64 TP53 TACC3 MSH2 MGMT ATM
33
Development EGFR signaling pathway 22
Show member pathways
 12.62 BRAF EGFR HRAS MTOR PIK3CA PIK3R1
34
Hepatocyte growth factor receptor signaling 74
Show member pathways
 12.6 TP53 PTEN PIK3R1 PIK3CA HRAS BRAF
35
MAPK signaling pathway 74
12.55 BRAF EGFR FGFR1 FGFR3 HRAS TP53
36
Development FGFR signaling pathway 22
Show member pathways
 12.54 PIK3R1 PIK3CA HRAS FGFR3 FGFR1
37
RhoGDI Pathway 64
Show member pathways
 12.53 PIK3R1 HRAS FGFR3 FGFR1 EGFR
38
Endometrial cancer 74
Show member pathways
 12.52 BRAF EGFR FGFR1 FGFR3 HRAS MSH2
39
Development Dopamine D2 receptor transactivation of EGFR 22
Show member pathways
 12.51 PIK3R1 PIK3CA HRAS EGFR
40
Development VEGF signaling via VEGFR2 - generic cascades 22
Show member pathways
 12.5 PIK3R1 PIK3CA HRAS BRAF
41
G-protein signaling RAC1 in cellular process 22
Show member pathways
 12.5 PIK3R1 PIK3CA MTOR HRAS FGFR3 FGFR1
42
Toll Comparative Pathway 64
Show member pathways
 12.45 TP53 PIK3R1 PIK3CA HRAS FGFR1
43
B Cell Receptor Signaling Pathway 67
Show member pathways
 12.45 PTEN PIK3R1 PIK3CA MTOR HRAS
44
Immune response Fc epsilon RI pathway 22
Show member pathways
 12.44 PTEN PIK3R1 PIK3CA HRAS
45
Focal adhesion 74
12.44 PTEN PIK3R1 PIK3CA HRAS EGFR BRAF
46
Development Ligand-independent activation of ESR1 and ESR2 22
Show member pathways
 12.43 EGFR HRAS PIK3CA PIK3R1
47
NF-kappaB Pathway 70
Show member pathways
 12.43 ATM EGFR FGFR1 FGFR3 HRAS MTOR
48
Signaling by VEGF 66
Show member pathways
 12.42 PIK3R1 PIK3CA MTOR HRAS
49
PDGFR-beta signaling pathway 61
Show member pathways
 12.42 BRAF EGFR MTOR PIK3CA PIK3R1 PTEN
50
Signaling by FGFR2 66
Show member pathways
 12.41 PIK3R1 PIK3CA HRAS FGFR3 FGFR1 BRAF
Sources

GO Terms for Gliosarcoma

About this section

Biological processes related to Gliosarcoma according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 protein phosphorylation GO:0006468 10.23 ATM BRAF EGFR FGFR1 FGFR3 MTOR
2 positive regulation of ERK1 and ERK2 cascade GO:0070374 10.22 PTEN HRAS FGFR3 EGFR BRAF
3 negative regulation of neuron apoptotic process GO:0043524 10.17 PIK3CA MSH2 HRAS BRAF
4 regulation of cell cycle GO:0051726 10.15 TP53 PTEN MSH2 HRAS ATM
5 negative regulation of apoptotic process GO:0043066 10.1 BRAF EGFR MGMT MTOR PIK3R1 PTEN
6 protein autophosphorylation GO:0046777 10.07 MTOR FGFR3 FGFR1 EGFR ATM
7 epidermal growth factor receptor signaling pathway GO:0007173 10.05 PIK3CA EGFR BRAF
8 phosphatidylinositol 3-kinase signaling GO:0014065 10.03 PTEN PIK3R1 PIK3CA
9 cellular response to gamma radiation GO:0071480 9.99 TP53 HRAS ATM
10 cell population proliferation GO:0008283 9.98 TP53 TACC3 TACC1 PTEN EGFR
11 positive regulation of lamellipodium assembly GO:0010592 9.97 PIK3R1 PIK3CA MTOR
12 MAPK cascade GO:0000165 9.85 HRAS FGFR3 FGFR1 EGFR BRAF
13 determination of adult lifespan GO:0008340 9.8 TP53 MSH2 ATM
14 regulation of axon regeneration GO:0048679 9.58 PTEN BRAF
15 response to stress GO:0006950 9.54 ATM MTOR
16 regulation of nucleobase-containing compound metabolic process GO:0019219 9.48 MTOR ATM
17 cellular response to endogenous stimulus GO:0071495 9.4 FGFR3 FGFR1
18 phosphorylation GO:0016310 9.32 PIK3R1 PIK3CA MTOR FGFR3 FGFR1 EGFR
19 positive regulation of miRNA maturation GO:1903800 9.26 TP53 MYCN EGFR

Molecular functions related to Gliosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transferase activity GO:0016740 9.92 PIK3CA MTOR MGMT FGFR3 FGFR1 EGFR
2 protein tyrosine kinase activity GO:0004713 9.8 FGFR3 FGFR1 EGFR BRAF
3 protein kinase activity GO:0004672 9.76 ATM BRAF EGFR FGFR1 FGFR3 MTOR
4 fibroblast growth factor receptor activity GO:0005007 9.67 FGFR3 FGFR1
5 nucleotide binding GO:0000166 9.65 SEPTIN14 PIK3CA MTOR MSH2 HRAS FGFR3
6 kinase activity GO:0016301 9.32 PIK3R1 PIK3CA MTOR FGFR3 FGFR1 EGFR
Sources

Sources for Gliosarcoma

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....